Business Development in an Era of Transformative Therapies

July 25, 2019 8:00 AM - 10:00 AM

MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139

Add to Calendar 7/25/2019 8:00:00 AM 7/25/2019 10:00:00 AM Business Development in an Era of Transformative Therapies

The future of therapeutics capable of treating, curing, and even entirely preventing many previously life-threatening illnesses has arrived! Whether it is developing drugs for molecular targets rather than specific diseases, replacing/correcting specific genes, or introducing cells engineered with bespoke features or payloads, a new dawn is upon us. For business development leaders this presents unusual and unprecedented challenges. How do unproven development pathways, uncertain and fluctuating markets sizes, and the potential for value-based pricing and payments affect how deals are negotiated and structured? Join us for a discussion among biopharma business development and finance leaders in this emerging space as they share their thoughts on creating value through business and corporate development activities in the context of the radical new technologies that are changing the practice of medicine.

 MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139
Vice President of Corporate and Business Development, Voyager Therapeutics
Allen Nunnally serves as vice president and head of corporate and business development at Voyager Therapeutics, a public gene therapy company focused on neurological disease. His life sciences experience spans 17 years with a focus on genetically- and genomically-driven technologies and biopharmaceuticals. Prior to Voyager, Mr. Nunnally served as vice president of corporate and business development and associate general counsel at Foundation Medicine, where he led transactions relating to its biopharmaceutical business in companion diagnostics and comprehensive genomic profiling for oncology and directed the company’s intellectual property strategy. Mr. Nunnally represented Foundation Medicine from Series B financing through its IPO and co-led the expansive R&D collaboration at the core of Foundation Medicine’s strategic transaction with Roche through which it first acquired a majority interest in that company. Mr. Nunnally previously spent 10 years at the law firm Wilmer, Cutler, Pickering, Hale and Dorr LLP, where he represented organizations ranging from Fortune 500 biopharma companies to early-stage biotech startups. Mr. Nunnally received a B.A. from Amherst College, where he double majored in in biology and law, jurisprudence and social thought, and a J.D. from Boston University School of Law with a concentration in intellectual property law.